Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2

By M. Humbert, R. Barst, I. Robbins, R. Channick, N. Galiè, A. Boonstra, L. Rubin, E. Horn, A. Manes, G. Simonneau. European Respiratory Journal, 2004

660 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/483829e53f664a9f2eddfa236f2343abbf3cff8d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, background): “Diabetes 19 (8) 30 (12) 13 (10) 17 (14)§”
• Pulmonary arterial hypertension (2013, background): “echocardiographic and Doppler variables, and time to clinical worsening [107,225-228].”
• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006, neutral): “In the one other placebo-controlled combination therapy trial that has been published to date, Humbert and colleagues randomized 33 patients with PAH initiating intravenous epoprostenol to receive either bosentan or placebo (18).”
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008, background): “Two randomized, placebo-controlled trials have been published (17, 23).”